Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
DarioHealth ( (DRIO) ) has provided an update.
On September 18, 2025, DarioHealth Corp. amended and restated the certificates of designation for its Series A-1, Series C, and Series D preferred stocks. These changes were made to accelerate the mandatory conversion of preferred shares into common stock or pre-funded warrants, allowing holders to receive accrued dividends as well. This strategic move is expected to streamline the company’s capital structure without issuing new securities.
The most recent analyst rating on (DRIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
Spark’s Take on DRIO Stock
According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.
DarioHealth’s overall stock score is primarily impacted by its financial challenges, including ongoing losses and high leverage. While technical indicators suggest a bearish trend, the company’s strategic initiatives and leadership changes provide some optimism for future growth.
To see Spark’s full report on DRIO stock, click here.
More about DarioHealth
DarioHealth Corp. operates in the digital health industry, offering innovative solutions for chronic condition management. The company’s primary products focus on digital therapeutics and health monitoring tools, aiming to improve patient outcomes and reduce healthcare costs.
Average Trading Volume: 19,429
Technical Sentiment Signal: Sell
Current Market Cap: $15.79M
See more insights into DRIO stock on TipRanks’ Stock Analysis page.